Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
Dec 10, 2024 · Enzyme responsible for fatty acid may be IPF therapeutic target. Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Trial: LYT-100 better than Esbriet in slowing lung function decline in IPF December 20, 2024; Ways to handle the isolation that can come with the holidays December 17, 2024; Enrollment hits 75% for Phase 2b clinical trial of Haduvio for IPF December 13, 2024; Dealing with grief during a season of joy December 10, 2024; First patient dosed in …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
Aug 16, 2019 · To address some misconceptions about the prognosis of pulmonary fibrosis and life expectancy of patients, we’ve put together some frequently asked questions (and answers) to help:<. What causes pulmonary fibrosis? Some cases of pulmonary fibrosis occur without known cause (this is called idiopathic pulmonary fibrosis).Other cases are caused by exposure to environmental hazards (such as ...
Bexotegrast reverses signs of IPF lung scarring in Phase 2a trial
May 17, 2024 · The Phase 2a imaging study (NCT05621252) enrolled 10 IPF patients. Participants were randomly assigned, with seven receiving 160 mg of once-daily bexotegrast, and three given a matching placebo for 12 weeks.
Enzyme responsible for fatty acid may be IPF therapeutic target
3 days ago · Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study identifying the enzyme as a potential therapeutic target for the condition. Experiments showed that FASN was ...
New prototype therapy may repair IPF lung scarring by …
Apr 26, 2024 · The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial that’s evaluating CMR316, an investigational inhalable therapy similar to the designed prototype. “Most drugs act by slowing the progression of disease; our approach is to make drugs that control cell fate to stop or reverse the disease process,” Peter G. Schultz, PhD, president and CEO of Scripps ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
Jun 7, 2024 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a 1.1% increase in the placebo.
BMS-986278 declared breakthrough therapy for progressive PF
Oct 27, 2023 · Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary clinical evidence showing the investigational therapy may improve at least one clinically relevant outcome significantly, compared with available therapies.
Now you know: Updates from my journey living with IPF
Nov 5, 2024 · I wanted to take the opportunity this week to update you on topics I’ve discussed in several recent columns. My bronchoscopy. Diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I was fortunate to receive a bilateral lung transplant in July 2021. In December 2022, my care team discovered my left bronchus had narrowed.I underwent several balloon dilations, but these only ...
About Us – Pulmonary Fibrosis News
Pulmonary Fibrosis News is a digital platform intended to provide the pulmonary fibrosis (PF) community with the most recent news and information on PF, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on Pulmonary Fibrosis News are original content produced by in-house writers and editors. . …